Apollo Hospitals Enterprise Ltd (AHEL) will acquire International Finance Corporation’s (IFC) 31% stake in its subsidiary Apollo Health and Lifestyle Ltd (AHLL) for ₹1,254 crore, consolidating ownership and strengthening its integrated healthcare strategy.
The company’s board has approved definitive agreements to purchase a little over 41.65 crore equity shares, representing 30.58% held jointly by IFC and IFC EAF Apollo Investment Company. Once completed, AHLL will become a wholly-owned subsidiary, with 99.42% held by AHEL and the remaining shares in the ESOP pool.
The acquisition is aimed at streamlining ownership, improving operational efficiencies, and deepening integration with Apollo’s diagnostic and primary care services. AHLL operates across four verticals – primary care and diagnostics, women’s health and birthing, ambulatory services, and dialysis and dental care. Consolidation is expected to allow Apollo to sharpen its focus on high-potential segments and strengthen capital allocation.
Suneeta Reddy, Managing Director of AHEL, said the move will “allow for sharper capital allocation and a greater focus on select high-potential segments,” positioning AHLL as a key driver of profitability and return on capital employed within Apollo’s portfolio. Sangita Reddy, Joint Managing Director, acknowledged IFC’s role as a growth partner and added that complete ownership will enable AHLL to “scale more effectively, innovate faster, and serve patients with more personalised and accessible care models.”
In parallel, Apollo has announced a ₹573 crore investment to establish a comprehensive oncology centre in Gurugram. The facility is expected to add capacity to treat 350 additional patients annually by FY 2029, aligning with the group’s strategy to expand specialized care infrastructure in high-demand areas.
Apollo’s move comes at a time when consolidation is becoming a defining trend in the Indian hospital and diagnostics sector. Recent years have seen large players streamline subsidiaries and expand specialized verticals to drive both profitability and scale. For example, Aster DM Healthcare has advanced an aggressive bed expansion strategy through mergers and acquisitions, while Manipal Hospitals has integrated diagnostic and specialty services into its portfolio following significant private equity backing. In diagnostics, players like Metropolis Healthcare and Dr Lal PathLabs have also pursued inorganic growth to build deeper regional networks and standardize operations.
The oncology expansion further aligns with broader industry momentum. Indian hospital chains are prioritizing cancer care facilities, responding to both rising incidence and patient demand for integrated, advanced therapies. Analysts note that oncology centres have emerged as high-growth, capital-intensive verticals, attracting both hospital operators and private equity investors.
By consolidating AHLL and committing fresh investment in oncology, Apollo is reinforcing its position as a vertically integrated healthcare provider, spanning preventive, diagnostic, and tertiary care. For investors and policymakers, the development underscores how India’s leading healthcare companies are reorganizing portfolios to capture demand in specialized and chronic care segments, while building efficiencies across their networks.
